bristar immunotech
Better T Cell Therapy
Better Patient Outcomes
bristar immunotech
IN CHINA
HELPING PATIENTS
GLOBALLY
bristar immunotech
PIONEERING CELLULAR
IMMUNOTHERAPIES
bristar immunotech
PATIENTS
FIRST
News
- 2023-03-23
BriSTAR Immunotech to Present its Novel Cell Therapy for Acute Myeloid Leukemia at the 2023 AACR Annual Meeting
March 23, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy platform at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
- 2023-01-31
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference
January 31, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer, James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Marquis during February 6-9, 2023.
- 2023-01-19
BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS
January 19, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023, in Austin, Texas.
About us
Our team at BriSTAR Immunotech is dedicated to the development and commercialization of innovative T cell immunotherapy products for the treatment of cancer and viral infections with urgent unmet medical needs.
We leverage our proprietary STAR-T platform to engineer next-generation T cell therapies for treating hematological malignancies and solid tumors. The STAR-T platform combines the advantages of CAR-T (Chimeric Antigen Receptor T-Cell immunotherapy) and TCR-T (T Cell Receptor T-cell immunotherapy) to produce mono- or bi-specific T cell therapies.
The promising antitumor actions of STAR-T cell therapies include better antigen sensitivity and stronger tumor infiltration. These properties are critical for achieving better responses in cancer patients, especially in treating solid tumors.
-
2018
Established In
-
60+
Employees
-
3500m²
37,600 sq.ft. R&D center
-
8+
Important Publications
Platform
Technology
Manufacturing
Pioneering Technology Platform
STAR-T & enTCR-T
Technology
Pioneering Technology Platform
STAR-T & enTCR-T
Manufacturing
Pipeline
Our product pipeline is designed to address urgent unmet clinical needs in hematologic malignancies and solid tumors.
READ MOREStay In Touch With BriSTAR Immunotech
Send our team your questions | Sign up to receive news updates